With multiple viruses still going round the world at different times in different seasons it is hard to predict the severity of winter respiratory viruses occuring this year; making it difficult to plan staffing levels and ensure adequate stock levels of the devices and equipment required to cope with any possible surge. Respiratory Syncytial Virus (RSV) was first discovered in 1956 and is a virus that comes round at least annually to most countries, so maybe now is a good time to think ahead and be prepared?
What is RSV?
Respiratory syncytial virus is an enveloped RNA virus and is in the same family as the human parainfluenza viruses and mumps and measles viruses. RSV is one of the common viruses that cause coughs and colds in winter usually causing mild respiratory infection in adults and children, but it can be severe in infants who are at increased risk of acute lower respiratory tract infection. It is the most common cause of bronchiolitis (inflammation of the small airways in the lung) in children aged under 2 years and pneumonia in children younger than 1 year of age in the United States [1].
Public Health England monitors levels of RSV activity in England and Wales and publishes information throughout the RSV season [2]. Advice on the symptoms, diagnosis, treatment, management and epidemiology of RSV can be found at Respiratory syncytial virus (RSV): guidance, data and analysis – GOV.UK (www.gov.uk).
How is it transmitted?
RSV is transmitted by large droplets and by secretions from contact with an infected person. The virus can survive on surfaces or objects for approximately 4 to 7 hours.
The incubation period (the delay between infection and the appearance of symptoms) is between 3 to 5 days[1].
What are the symptoms and diagnosis?
RSV infection causes symptoms similar to a cold, including rhinitis (runny nose, sneezing or nasal congestion), cough, and sometimes fever. Ear infections and croup (a barking cough caused by inflammation of the upper airways) can also occur in children. The bronchiolitis suffered makes breathing harder and may cause difficulty with feeding.
During the RSV season a laboratory diagnosis is not always necessary as infection can be managed. Specific laboratory tests to confirm RSV require a sample to be taken from the nose and throat [3].
What are the available treatments?
There is no specific treatment suitable for general use, and treatment is therefore aimed at supporting the patient and relieving symptoms. Ribavirin is an anti-viral drug licensed for treatment of RSV infection, which is sometimes used, either by inhalation for less severe or intravenously in the management of severe illness. Its effectiveness is not established and it may be associated with toxicity [6]. As well as the above supportive treatments, hydration with intravenous fluids and humidified oxygen may be administered such as…
Is immunisation available?
Palivizumab, a monoclonal antibody therapy, is licensed in the UK for the prevention of serious lower respiratory tract infection caused by RSV in infants at high risk of infection and is listed on the NICE website [4].
When does RSV circulate?
In temperate climates such as the UK, RSV occurs regularly each year. Epidemics generally start in October and last for 4 to 5 months, peaking in December. The sharp winter peak varies little in timing or magnitude, in contrast to influenza virus infection which is much less predictable in its timing.
Are there any risks associated with RSV?
For most people, RSV infection causes a mild respiratory illness. For a small number of people who are at risk of more severe respiratory disease, RSV infection might cause pneumonia or even death.
According to the UK Health Security Agency (UKHSA) over 60% of children have been infected by their first birthday and over 80% by 2 years of age. Unfortunately, the antibodies that develop following early childhood infection do not prevent further RSV infections in the future. The degree to which adults are affected by RSV remains unknown.
What impact does RSV have on high-risk groups?
The very young (under 1 year of age) and the elderly are at the greatest risk. While most RSV infections usually cause mild illness, infants aged less than 6 months frequently develop the most severe disease such as bronchiolitis and pneumonia, which may result in hospitalisation. Children born prematurely, or with underlying chronic lung disease, and the elderly with chronic disease are also at increased risk of developing severe disease.
Only a minority of adult infections are diagnosed, as RSV is not widely recognised as a cause of respiratory infections in adults. Elderly patients are frequently not investigated microbiologically, as there are fewer viruses present in their respiratory secretions compared with children. This results in the number of adult infections being underestimated.
RSV Prevention
RSV is highly contagious. Each year in the USA, an estimated 2.1 million outpatient visits occur in children younger than 5 years of age due to RSV infection. There are some steps you should take to prevent its spread. The most effective means of protection are some of the simplest, such as:
Armstrong Medical Ltd is a limited company registered in Northern Ireland
Wattstown Business Park, Newbridge Road, Coleraine, Co. Derry/Londonderry, BT52 1BS, United Kingdom
VAT Number: GB432578934
Company Number: NI025560
Streamlining respiratory therapy delivery.
Improving comfort in Neonatal Care.
Improving patient safety in Anaesthesia.
Providing virtual and face to face training sessions.
Continuous Positive Airway Pressure device and consumables to support spontaneously breathing patients with respiratory failure.
Breathing circuits to support the clinical management of all patients on Intensive Care, NIV and transportation ventilators.
Adult and Neonatal resuscitation circuitry and accessories for anaesthesia, physiotherapy and resuscitation.
Medical devices, circuits and accessories suitable for airway management and ventilation in the perioperative and emergency setting.
A simple but effective draping system to prevent patient heat loss and associated hypothermia.
Accessories designed to deliver aerosolised micro-drug particles from a Metered Dose Inhaler (MDI) canister.
Creating Support for Life.
Armstrong Medical’s monthly blog.
Keep up to date with news, events and seminars.
Vacancies at Armstrong Medical.
News on upcoming events.
Armstrong Medical’s policies.
Cookie | Duration | Description |
---|---|---|
cookielawinfo-checkbox-advertisement | 1 year | Set by the GDPR Cookie Consent plugin, this cookie is used to record the user consent for the cookies in the "Advertisement" category . |
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
CookieLawInfoConsent | 1 year | Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie. |
elementor | never | This cookie is used by the website's WordPress theme. It allows the website owner to implement or change the website's content in real-time. |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |
Cookie | Duration | Description |
---|---|---|
wp-wpml_current_language | session | WordPress multilingual plugin sets this cookie to store the current language/language settings. |
Cookie | Duration | Description |
---|---|---|
_ga | 1 year 1 month 4 days | The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors. |
_ga_* | 1 year 1 month 4 days | Google Analytics sets this cookie to store and count page views. |
_gat_gtag_UA_* | 1 minute | Google Analytics sets this cookie to store a unique user ID. |
_gid | 1 day | Installed by Google Analytics, _gid cookie stores information on how visitors use a website, while also creating an analytics report of the website's performance. Some of the data that are collected include the number of visitors, their source, and the pages they visit anonymously. |